Phase 3 Readout

VERA: Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic

Name: Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic
Start: 2028-07-01
End: 2028-07-01

July 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: July 1, 2028
Company: Vera Therapeutics, Inc. (VERA)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effic

July 1, 2028

VERA overview →

Company: Vera Therapeutics, Inc. (VERA)
Indication: IgA Nephropathy; Berger Disease